Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Other Non-Current Assets (2020 - 2025)

Ovid Therapeutics' Other Non-Current Assets history spans 6 years, with the latest figure at $1.9 million for Q2 2025.

  • For Q2 2025, Other Non-Current Assets rose 684.96% year-over-year to $1.9 million; the TTM value through Jun 2025 reached $1.9 million, up 684.96%, while the annual FY2024 figure was $92000.0, 95.24% down from the prior year.
  • Other Non-Current Assets reached $1.9 million in Q2 2025 per OVID's latest filing, roughly flat from $1.9 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.9 million in Q4 2023 to a low of $80114.0 in Q2 2022.
  • Average Other Non-Current Assets over 5 years is $1.1 million, with a median of $1.1 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 2310.01% in 2023, then crashed 95.24% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $260126.0 in 2021, then soared by 642.24% to $1.9 million in 2022, then rose by 0.01% to $1.9 million in 2023, then plummeted by 95.24% to $92000.0 in 2024, then skyrocketed by 1998.91% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Other Non-Current Assets are $1.9 million (Q2 2025), $1.9 million (Q1 2025), and $92000.0 (Q4 2024).